type 2 diabetes mellitus
Conditions
Interventions
acarbose 150-300 mg/day
voglibose 0.9 mg/day
Sponsors
Chubu Rousai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 diabetic patients who have been treated with voglibose 0.9 mg/day for 3 months or more. 2)HbA1c of 6.5%(NGSP) or more.
Exclusion criteria
Exclusion criteria: 1)Patients with ACS within 6 months 2)Patie nts treating with insulin 3)Patients who have undergone a gastrectomy or abdominal surgery 4)Patients with sever hepatic dysfunction or renal dysfunction 5)Patients with serious ketosis, diabetic coma, pre-coma 6)Patients with sever infection, pre-/after recent operation , serious trauma 7)Patients with gastrointestinal disorders such as diarrhea and vomitting 8)Patients with history of sensitivity to acarbose 9)Women who are pregnant or with a possibility of pregnancy 10)Other patients whom the investigator deems unsuitable for inclusion in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow Mediated Dilation test | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, fasting blood glucose/triglyceride and postprandial (2h) blood glucose/triglyceride, LDL-cholesterol, HDL-cholesterol, urinary albumin extraction, body weight, blood pressure | — |
Countries
Japan
Contacts
Public ContactEitaro Nakashima
Chubu Rousai Hospital Dept. of Diabetes and Endocrinology
Outcome results
None listed